su011248

Prostatic Neoplasms

PfizerPhase 3Dormant

B

58/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 51/ 100
Competitive Position: 73/ 100

Competitive context

56 Active assets in the Prostatic Neoplasms cohort.

Asset / Sponsor	Phase	Rating
Docetaxel Merck Sharp & Dohme LLC	Phase 4	BBB
PREDNISONE TABLETS Merck Sharp & Dohme LLC	Phase 3	BBB
Abiraterone Acetate Qilu Pharmaceutical Co., Ltd.	Phase 3	BB
LEUPROLIDE Dana-Farber Cancer Institute	Phase 4	BB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Eli Lilly and Company	Phase 3	BB

View all 50 →

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant

BBB

Indicative ·

75 / 100

Pancreatic Neuroendocrine TumorDormant

BB

Indicative ·

69 / 100

Renal Cell CarcinomaDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.